Todos os estudos
RecrutamentoNAINTERVENCIONISTA

Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura

This research is exploring a new, less invasive approach to treating a rare blood condition called immune thrombotic thrombocytopenic purpura (iTTP). Currently, patients need daily plasma exchange (PEX), which can be time-consuming and have side effects. This trial aims to see if a treatment combination of immunosuppressive medicines, caplacizumab (a medicine that stops blood clots), and plasma infusions (without daily PEX) is just as effective and safe. By potentially removing the need for daily PEX, this new method could make treatment much easier for patients, reduce hospital stays, and lower the risk of common complications associated with the standard treatment.

Em resumo

Status
Recrutamento
Fase
NA
Patrocinador
University Hospital, Rouen
Meta de inscrição
131
Iniciar
10 Apr 2024
Conclusão estimada
01 Ago 2026

Sobre o que é este estudo?

Immune thrombotic thrombocytopenic purpura, or iTTP, is a rare but serious blood condition. In iTTP, your body mistakenly attacks a protein called ADAMTS13, which is important for controlling blood clotting. This leads to tiny clots forming in your blood vessels, which can cause problems in various organs and lower your platelet count.

The usual treatment for iTTP involves daily plasma exchange (PEX). This is a procedure similar to dialysis, where some of your blood is taken out, treated, and then returned. While PEX is effective, it’s a big undertaking. It takes a lot of time, often means spending more time in hospital, and can come with risks and side effects like problems with the catheter used or reactions to the plasma. Because of this, doctors are always looking for ways to make treatment better and easier for patients.

This study is investigating a new treatment approach that aims to avoid daily plasma exchange. It combines medicines that calm down the immune system (immunosuppressive agents), a special drug called caplacizumab that helps prevent new clots, and plasma infusions (giving plasma directly into your bloodstream, but not as part of a daily exchange). The goal is to see if this combination can effectively treat iTTP without the need for the invasive and time-consuming daily plasma exchange. If successful, this could significantly improve the treatment experience for people with iTTP, making it safer, more comfortable, and leading to shorter hospital stays.

Pontos principais

  • This study is testing a new way to treat iTTP without daily plasma exchange.
  • It combines immune-calming drugs, a clot-preventing medicine (Caplacizumab), and plasma infusions.
  • The goal is to make iTTP treatment less invasive and potentially safer.
  • Participation involves receiving study treatments and having regular check-ups.
  • This could reduce hospital time and complications associated with standard treatment.

Quem pode ser elegível?

To join this study, generally, you must be an adult aged 18 or older. You would need to have been diagnosed with iTTP based on specific clinical and lab tests. This diagnosis usually involves having a certain level of platelets (tiny blood cells involved in clotting) and creatinine (a waste product in your blood) after other causes have been ruled out. If you've had iTTP before, the exact criteria might be slightly different.

There are also some important reasons why you might not be able to join. For example, if your platelet count is too high before starting plasma treatment, or if your condition is thought to be a different type of blood disorder. Additionally, if you have other serious health issues like uncontrolled cancer, severe neurological problems (like significant seizures or a coma), or if you are pregnant, you would not be able to take part. Women who could become pregnant would need to be using effective contraception.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Have you been diagnosed with iTTP (or a similar past episode)?
  3. Are you currently not pregnant?
  4. Are you able to use effective contraception if you're a woman who could become pregnant?
  5. Do you have a platelet count 100 G/L or less before starting plasma treatment?
  6. Do you not have other serious conditions like uncontrolled cancer or severe neurological problems?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

This study is designed to evaluate a new treatment approach, so if you were to participate, you would receive a combination of medicines: immunosuppressive drugs to calm your immune system, caplacizumab (a drug to help prevent blood clots), and plasma infusions (where you receive plasma directly into your bloodstream). The frequency and duration of these treatments would be guided by the study doctors, and they would monitor your condition closely.

Throughout the study, you would attend regular appointments for check-ups, blood tests, and to assess how you are responding to the treatment. These visits are important for the doctors to understand how well the new approach is working and to ensure your safety. While the exact total duration isn't specified, typical clinical trials for new treatments involve several weeks or months of active treatment and follow-up. You would receive detailed information about the schedule before deciding to join.

Riscos e benefícios potenciais

Taking part in any medical study has potential benefits and risks. A potential benefit of this study is the chance to receive a new, potentially less invasive treatment for iTTP, which could lead to fewer complications and a shorter hospital stay compared to the current standard care involving daily plasma exchange. However, this is an investigational approach, and there's no guarantee it will be more effective or safer for you. Any medications, including those used in this study, can have side effects, and the research team will explain potential risks linked to the immunosuppressants, caplacizumab, and plasma infusions. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Localizações (30)

  • Chu Amiens
    Código postal verificado
    Amiens, France· Recrutamento
  • Chu Angers
    Código postal verificado
    Angers, França· Recrutamento
  • Chru Besanon
    Código postal verificado
    Besançon, França· Recrutamento
  • Chu Bobigny
    Código postal verificado
    Bobigny, France· Recrutamento
  • Hopital Jean Verdie
    Código postal verificado
    Bondy, France· Recrutamento
  • Chu Bordeaux
    Código postal verificado
    Bordéus, França· Recrutamento
  • Chu Clermont-Ferrand
    Código postal verificado
    Clermont-Ferrand, França· Recrutamento
  • Chu Lille
    Código postal verificado
    Lille, France· Recrutamento
  • Chu Limoges
    Código postal verificado
    Limoges, França· Ainda não recrutando
  • Chu Edouard Herriot
    Código postal verificado
    Lyon, França· Recrutamento
  • Ap-Hm La Conception
    Código postal verificado
    Marselha, França· Recrutamento
  • Chu Montpellier
    Código postal verificado
    Montpellier, France· Recrutamento

Perguntas frequentes

What is iTTP?

iTTP (immune thrombotic thrombocytopenic purpura) is a rare blood disorder where your immune system attacks a protein, leading to tiny blood clots and low platelet counts.

What is 'plasma exchange' and why is it usually given?

Plasma exchange is a procedure similar to dialysis that removes harmful substances from your blood. It's normally used daily for iTTP to remove problem proteins and provide healthy ones.

What is Caplacizumab?

Caplacizumab is a medicine that helps prevent the tiny blood clots that cause problems in iTTP.

Will I still get plasma if I join this trial?

Yes, you will still receive plasma, but it will be given as infusions (directly into your bloodstream) instead of daily plasma exchange.

Quem está conduzindo este estudo?

The study title is about 'Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura'. It is a clinical trial being conducted by medical researchers.

Como saber mais

Ygal Benhamou, Pr

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "Efficacy and Safety of Immunosuppression, Caplacizumab and P…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.